{"id":969595,"date":"2026-06-02T14:40:43","date_gmt":"2026-06-02T18:40:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/"},"modified":"2026-06-02T14:40:43","modified_gmt":"2026-06-02T18:40:43","slug":"legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/","title":{"rendered":"Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">\n          <em>Promising Phase 1 data for LB2501, a potential first<\/em><br \/>\n          <em>\u2011<\/em><br \/>\n          <em>in<\/em><br \/>\n          <em>\u2011<\/em><br \/>\n          <em>class CD19\/CD20 dual<\/em><br \/>\n          <em>\u2011<\/em><br \/>\n          <em>targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B<\/em><br \/>\n          <em>\u2011<\/em><br \/>\n          <em>cell malignancies<\/em>\n        <\/li>\n<li style=\"margin-bottom:6pt\">\n          <em>An ORR of 100% (6\/6) was observed in the dose level 2 cohort, including CR rate of 83.3% (5\/6) in patients with relapsed\/ refractory NHL<\/em>\n        <\/li>\n<li style=\"margin-bottom:6pt\">\n          <em>Data demonstrate robust in vivo CAR<\/em>&#8211;<em>T expansion without lymphodepleting chemotherapy <\/em><\/li>\n<li style=\"margin-bottom:6pt\">\n          <em>Favorable safety profile: no DLTs, no SAEs, no ICANS, CRS <\/em><br \/>\n          <em><br \/>\n            <u>&lt;<\/u><br \/>\n          <\/em><br \/>\n          <em>Grade 2<\/p>\n<p><\/em>\n        <\/li>\n<\/ul>\n<p align=\"justify\">BRIDGEWATER, N.J., June  02, 2026  (GLOBE NEWSWIRE) &#8212; Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501, its investigational <em>in vivo <\/em>CD19\/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (R\/R B-NHL), will be presented during a late-breaking session at the European Hematology Association (EHA) 2026 Congress, taking place June 11-14, 2026, in Stockholm, Sweden.<\/p>\n<p align=\"justify\">\u201cThe upcoming presentation of Phase 1 LB2501 data in patients with B-cell malignancies represents an important step in advancing <em>in vivo<\/em> CAR-T approaches,\u201d said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. \u201cBy generating CAR-T cells directly within the patient, this approach has the potential to simplify treatment delivery and expand access for patients who may not be able to receive traditional CAR-T cell therapies. LB2501 is built on the TaVec\u2122 platform, which is a proprietary lentiviral vector engineered to enhance T-cell specificity, transduction efficiency, and safety, while restricting transduction of non-T cells.\u201d<\/p>\n<p align=\"justify\">\n        <strong>LB2501: Promising Phase 1 Trial of <\/strong><br \/>\n        <strong><br \/>\n          <em>In Vivo<\/em><br \/>\n        <\/strong><br \/>\n        <strong> CAR-T Data Demonstrate High Response Rates in B-cell Malignancies<\/strong>\n      <\/p>\n<p align=\"justify\">Data from 12 patients across two dose cohorts in an ongoing Phase 1 study evaluating LB2501 in patients with R\/R B-NHL provide early clinical evidence supporting the potential of an <em>in vivo<\/em> CAR-T approach in B-cell malignancies. LB2501 is designed to generate CAR-T cells directly within the patient following a single intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion.<\/p>\n<p align=\"justify\">As of April 1, 2026, 12 patients with R\/R B-NHL were treated across two dose levels (DL1 and DL2). Additional details will be presented at EHA 2026. Key findings from the abstract include:<\/p>\n<p align=\"justify\">\n        <strong>Efficacy Results<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">At DL2 (median follow-up for DL2 was 2.2 months [range, 2.0 to 3.8])\n<ul type=\"circle\">\n<li style=\"text-align:justify\">Objective response rate (ORR): 100% (6\/6)<\/li>\n<li style=\"text-align:justify\">Complete response rate (CR): 83.3% (5\/6)<\/li>\n<li style=\"text-align:justify\">All responses were ongoing at data cutoff\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Pharmacokinetics <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Dose-dependent <em>in vivo <\/em>CAR-T expansion observed<\/li>\n<li style=\"text-align:justify\">CAR-T cells detected in peripheral blood for up to 116 days\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Safety Results<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>No dose-limiting toxicities (DLTs), serious adverse events (SAEs), or deaths were observed<\/li>\n<li>Infusion-related reactions occurred in 75% of patients, all of which were \u2264 Grade 2<\/li>\n<li>Cytokine release syndrome (CRS) occurred in 66.7% of patients, all of which were \u2264 Grade 2<\/li>\n<li>No immune effector cell-associated neurotoxicity syndrome (ICANS) was reported<\/li>\n<li>Grade \u22653 lentiviral vector-related and CAR-T-related adverse events were limited to decreased lymphocyte count and decreased neutrophil count\n<\/li>\n<\/ul>\n<p>\n        <strong>EHA Presentation (June 11-14, 2026)<\/strong>\n      <\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:19%;width:19%;min-width:19%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Abstract No.<\/strong>\n          <\/td>\n<td style=\"max-width:51%;width:51%;min-width:51%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Title<\/strong>\n          <\/td>\n<td style=\"max-width:30%;width:30%;min-width:30%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Information<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Abstract #LB5006<br \/>Late-Breaking Oral Presentation<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">First-in-human trial of LB2501, an <em>in vivo<\/em> CD19\/CD20 dual targeting CAR-T therapy, in relapsed\/refractory B-Cell NHL<\/p>\n<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Session ID: <\/strong>s204<br \/><strong>Date\/Time:<\/strong> Sunday, June 14, 2026, 9:15-10:45 AM CEST<br \/><strong>Location:<\/strong> Nobel Hall<\/td>\n<\/tr>\n<\/table>\n<p align=\"left\">\n        \n      <\/p>\n<p align=\"justify\">\n        <strong>ABOUT LB2501<\/strong><br \/>\n        <br \/>LB2501 is an investigational, potential first-in-class CD19\/CD20 dual-targeting <em>in vivo<\/em> CAR-T therapy designed to generate CAR-T cells directly within the patient following a single intravenous infusion. It is being evaluated in an ongoing Phase 1, open-label study <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qk28T0yrknh8pG_NnJ6OuR-EkVr-3ZqAcB95c3IGnlhEWKD6ox5FlcAEfu0TsB-aCQKxigTOBfb36f-qZrCcFsdZuY-pJEqW-9i5verO1lF3LC83kycZ4Ez7JYAsBCDw\" rel=\"nofollow\" target=\"_blank\">NCT07002112<\/a>) in patients with relapsed\/refractory B-cell malignancies to assess safety, tolerability, and preliminary efficacy.<sup>i<\/sup><\/p>\n<p align=\"justify\">\n        <strong>ABOUT B-CELL NON-HODGKIN LYMPHOMA<\/strong><br \/>\n        <br \/>Non-Hodgkin lymphoma (NHL) is a group of cancers that originate in lymphocytes, a type of white blood cell that plays a key role in the body\u2019s immune system.<sup>ii<\/sup> B-cell lymphomas account for approximately 85% of NHL cases and arise from abnormal growth of B lymphocytes (B cells), which are responsible for producing antibodies. These malignancies include a range of subtypes that vary in aggressiveness, from slow-growing to highly aggressive disease.<sup>iii<\/sup><\/p>\n<p align=\"justify\">\n        <strong>ABOUT\u00a0LEGEND BIOTECH<\/strong><br \/>\n        <br \/>With over 3,000 employees,\u00a0Legend Biotech\u00a0is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever.\u00a0Legend Biotech\u00a0is at the forefront of the CAR-T cell therapy revolution with CARVYKTI<sup>\u00ae<\/sup>, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson &amp; Johnson. Centered in\u00a0the United States,\u00a0Legend Biotech\u00a0is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI\u2019s patient access and therapeutic potential. From this platform,\u00a0Legend Biotech\u00a0plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.<\/p>\n<p align=\"justify\">Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M6hbX2a1lZy3qUwl3UsMtjdI5dkAOC9y7jeF1RpuXaFA_qKsWIr4jG2jYkmbZAbld1PvjMDJt75mLXt3axziFHHFsrFOW9AI2vmkbx1a_apemrAl5ydAdMQtXr3EqWS2RZqsgD1PxNyMNKaIoySSrRtPLknap1I8N3sgGXsI7m3NKqyOqv-Rplz7yOgPMKZK7E325BihimfP6fuWgBRsu7IRxAxn4gpxaR7yFS-3nvqiNu-ev9o8nVAyYkwUNq3qjS0vDze-T8KPDNzMr955-g==\" rel=\"nofollow\" target=\"_blank\">https:\/\/legendbiotech.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZWM9sf4ay9zsTW1z1uSdY78JS7Td3biAQLINyL41C6lvjxDSsDJKNNUAwur7YE6E2EER5Oqg9OsJXz4wREMrfN0vZxAgBclYP0NbSBiashOK9c3R0Y35axLvE5jwW7hprovosAT6WAlMUopZW1sdwFN_sOsXbGi_wMcXrKieVIC-a73G8BkH1vyfsil7tLYk4f2EDWlei3hEBQwDs4oJ2Q==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xHMmw1UdRKXuTYVr0E52Cui11SEMi63OE669W2xbPyholNhyJjlLwpXf94msIeBmpZBURV1olRZIG8fr0I0xBMLkRyp1d_3HwY74nOqXC5Gqi6g08fgcNleCwX91ZwvB\" rel=\"nofollow\" target=\"_blank\">Instagram,\u00a0<\/a>and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Uo0UACb1mYCglL8ZH9VoR1JKxGSQTijXdy8SSR_oM6dCZPNMrSZk6JuiDkofKTUQdkM3S1NkbrPcFnXhJrRZMifg17IpEG4gOv2a234_o30z9wLQvW0R6Za1s2PEXz24GE6PDXiRXObaEFtoFl3jLrYmXMNLUsYrmib8NAZzFLC7_ZRpAcmdIMd1V9cuU8R5e0uEWUS5Y6SSuco8ySVJJfmJ5ThuZkwXYgl2kQbODS8WMPVzEIJ6yvmh9NNrMxpumo_I05Kaa8_-gRUuZRteEXatJEN7wTBpFPvzyAsaSE_Io6ReakW24Mlqh_eNJmLa\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS<\/strong><\/p>\n<p>        <em>Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute \u201cforward-looking statements\u201d within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech\u2019s strategies and objectives, the potential benefits of the proprietary TaVec platform, the Phase 1 clinical trial of LB2501 and the potential benefits of LB2501, including its potential to be first-in-class. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech\u2019s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and\/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by Legend Biotech\u2019s third-party partners; uncertainties arising from challenges to Legend Biotech\u2019s patent or other proprietary intellectual property protection, including the uncertainties involved in the\u00a0U.S.\u00a0litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the \u201cRisk Factors\u201d section of Legend Biotech\u2019s Annual Report on Form 20-F filed with the\u00a0Securities and Exchange Commission\u00a0on\u00a0March 10, 2026. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release.\u00a0Legend Biotech\u00a0specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.<\/em>\n      <\/p>\n<p>\n        <strong>INVESTOR CONTACT:<\/strong><br \/>\n        <br \/>Jessie Yeung<br \/>Tel: (732) 956-8271<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WQ0yvpBeo4x98U2STGZ41lF-KqRrduqaDpzjits9bMHwVRes2JeCKcbWih1XPZPT4SgVpql-SDb-j3G0AXmwNie9YyRiIUcWVDLv3AxZy8652AjJu-m1Tu_Q3cDikaJS\" rel=\"nofollow\" target=\"_blank\">investor@legendbiotech.com<\/a><\/p>\n<p>\n        <strong>PRESS CONTACT:<\/strong><br \/>\n        <br \/>Kim Fox<br \/>Tel: (848) 388-8445<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l0D8rFKhKqvFcAbSp2DGlF1o4k8gBylBYtoBookqoJoouiUsnTsxSWbu8RUsbXnmP7Ba38E5p0D0DK0ByLOgap5beIvxta7OGQm63hVYCkCxpk877giy5x1ctLFyopvP\" rel=\"nofollow\" target=\"_blank\">media@legendbiotech.com<\/a><\/p>\n<p>\n        <sup>i<\/sup> ClinicalTrials.Gov. The CD19\/\u200bCD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed\/\u200bRefractory B-cell Malignancies. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M6hbX2a1lZy3qUwl3UsMtn76QXFsWd8Lz1spdD1945BLijI0wjCnN-D7SJ8t4qiVr-NySUS0Qxc8qy32FdE9sKpG8-FtQpQdwdEWp6CUaRkSTXvGurSRL8gCTWjJNruDhMRRfFwHqWXH3t9F28gmbQwnMr40h_u4tBAdwWV92D8=\" rel=\"nofollow\" target=\"_blank\">https:\/\/clinicaltrials.gov\/study\/NCT07002112<\/a>. Accessed May 2026<br \/><sup>ii<\/sup> American Cancer Society. \u201cWhat Is Non-Hodgkin Lymphoma?\u201d. Available at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M6hbX2a1lZy3qUwl3UsMtqK0jfOs_pMr2kthef8o543RcDeIH6QsbR0wn5G0vuC-ECeVRgXWFk8zrZ4DcPbqqz1Ii9VeWeWzsmTUOZKd0vpCQjR7DkteubAmNaZQkLHf1JJLt6Iu6DBa3FwPBjV0tpz2emj42W7Nfwk5z4QeinSHrHJQB43VJCJdhL9MLFoQ8nx5pgxqljqyzNFuoenMIluNDpOdvXZVOU7COzlcz2NB_OJx0vmYWLhcYnKMRPzeSQ7oYPq779zVu2AR9fEEtVJwlte62seCCR3cGehodYA=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.cancer.org\/cancer\/types\/non-hodgkin-lymphoma\/about\/what-is-non-hodgkin-lymphoma.html<\/a>.Accessed May 2026.<br \/><sup>iii<\/sup> American Cancer Society. \u201cTypes of B-cell Lymphoma.\u201d Available at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M6hbX2a1lZy3qUwl3UsMtqK0jfOs_pMr2kthef8o543RcDeIH6QsbR0wn5G0vuC-ECeVRgXWFk8zrZ4DcPbqq_pU-ZO7Q0Uv4qTEd-K7DymFZcKa3IDyxeX7l6gaJBSiAyJGTvJ6p9fJxV8Ngef6ZRVuwH7gYBdjNdPLPvsRtuxOx6nU3gLcEzCoOzzOof-q9Xjq5h3KFCb75KM5ylc3qOeNKsu1yGLgb-bGtquzLnHQdzaA8rvmFX57f8WhkXVamxT-O3UbBqzV1ElKp8lEgQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.cancer.org\/cancer\/types\/non-hodgkin-lymphoma\/about\/b-cell-lymphoma.html<\/a>.Accessed May 2026.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMDE2OCM3NjMxMzgyIzIxOTQ5NTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Nzc4ZTNmZTgtMDg0Mi00NzM1LTk0MDEtYmY0Y2EwZDJlZmRhLTEyMDY1MDUtMjAyNi0wNi0wMi1lbg==\/tiny\/Legend-Biotech-USA-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Promising Phase 1 data for LB2501, a potential first \u2011 in \u2011 class CD19\/CD20 dual \u2011 targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B \u2011 cell malignancies An ORR of 100% (6\/6) was observed in the dose level 2 cohort, including CR rate of 83.3% (5\/6) in patients with relapsed\/ refractory NHL Data demonstrate robust in vivo CAR&#8211;T expansion without lymphodepleting chemotherapy Favorable safety profile: no DLTs, no SAEs, no ICANS, CRS &lt; Grade 2 BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) &#8212; Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501, its investigational in vivo CD19\/CD20 dual-targeting CAR-T cell &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-969595","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Promising Phase 1 data for LB2501, a potential first \u2011 in \u2011 class CD19\/CD20 dual \u2011 targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B \u2011 cell malignancies An ORR of 100% (6\/6) was observed in the dose level 2 cohort, including CR rate of 83.3% (5\/6) in patients with relapsed\/ refractory NHL Data demonstrate robust in vivo CAR&#8211;T expansion without lymphodepleting chemotherapy Favorable safety profile: no DLTs, no SAEs, no ICANS, CRS &lt; Grade 2 BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) &#8212; Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501, its investigational in vivo CD19\/CD20 dual-targeting CAR-T cell &hellip; Continue reading &quot;Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-02T18:40:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMDE2OCM3NjMxMzgyIzIxOTQ5NTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)\",\"datePublished\":\"2026-06-02T18:40:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\\\/\"},\"wordCount\":1211,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMDE2OCM3NjMxMzgyIzIxOTQ5NTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\\\/\",\"name\":\"Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMDE2OCM3NjMxMzgyIzIxOTQ5NTI=\",\"datePublished\":\"2026-06-02T18:40:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMDE2OCM3NjMxMzgyIzIxOTQ5NTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMDE2OCM3NjMxMzgyIzIxOTQ5NTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/","og_locale":"en_US","og_type":"article","og_title":"Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) - Market Newsdesk","og_description":"Promising Phase 1 data for LB2501, a potential first \u2011 in \u2011 class CD19\/CD20 dual \u2011 targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B \u2011 cell malignancies An ORR of 100% (6\/6) was observed in the dose level 2 cohort, including CR rate of 83.3% (5\/6) in patients with relapsed\/ refractory NHL Data demonstrate robust in vivo CAR&#8211;T expansion without lymphodepleting chemotherapy Favorable safety profile: no DLTs, no SAEs, no ICANS, CRS &lt; Grade 2 BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) &#8212; Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501, its investigational in vivo CD19\/CD20 dual-targeting CAR-T cell &hellip; Continue reading \"Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-02T18:40:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMDE2OCM3NjMxMzgyIzIxOTQ5NTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)","datePublished":"2026-06-02T18:40:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/"},"wordCount":1211,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMDE2OCM3NjMxMzgyIzIxOTQ5NTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/","name":"Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMDE2OCM3NjMxMzgyIzIxOTQ5NTI=","datePublished":"2026-06-02T18:40:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMDE2OCM3NjMxMzgyIzIxOTQ5NTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMDE2OCM3NjMxMzgyIzIxOTQ5NTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/legend-biotech-announces-late-breaking-oral-presentation-at-eha-2026-showcasing-initial-phase-1-in-vivo-car-t-data-with-lb2501-in-non-hodgkin-lymphoma-nhl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/969595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=969595"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/969595\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=969595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=969595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=969595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}